Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
AstraZeneca
Moodys
Medtronic
Johnson and Johnson

Last Updated: January 31, 2023

Details for Patent: 7,799,761


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,799,761 protect, and when does it expire?

Patent 7,799,761 protects NOCTIVA and is included in one NDA.

This patent has forty-three patent family members in twenty-nine countries.

Summary for Patent: 7,799,761
Title:Pharmaceutical compositions including low dosages of desmopressin
Abstract: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 .mu.g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Inventor(s): Fein; Seymour H. (New Canaan, CT)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:10/706,100
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,799,761
Patent Claim Types:
see list of patent claims
Composition; Delivery; Dosage form;

Drugs Protected by US Patent 7,799,761

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Acerus Pharms NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,799,761

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 039092 See Plans and Pricing
Argentina 039794 See Plans and Pricing
Argentina 107948 See Plans and Pricing
Austria 333886 See Plans and Pricing
Australia 2002337419 See Plans and Pricing
Australia 2003233118 See Plans and Pricing
Australia 2003299480 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Dow
Johnson and Johnson
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.